CRX.L Regulatory News (CRX)

Cyprotex PLC

Board Change

4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the resignation of Katya Tsaioun, PhD, with immediate effect.

Dr Tsaioun has served as Cyprotex's Chief Scientific Officer and Director since the August 2010 acquisition of its U.S based subsidiary Apredica, where she was President and co-founder.

As part of the Apredica purchase agreements, Dr. Tsaioun planned to remain with the combined companies for two years. During her tenure at Cyprotex, Dr, Tsaioun led Cyprotex into three new markets: high content in vitro toxicology, in vitro topical and cosmetic testing, and genomic ADME services.

The Company wishes to extend its gratitude for Dr. Tsaioun's contributions as a Director and CSO and wishes her well in her future endeavours.

Enquiries:

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME Tox) properties of potential drugs, cosmetics, and agrochemicals and has worked with more than 700 partners ranging from small biotechs to large pharma companies. It is the only company in the world with in-house in vitro (test tube) and in silico (computer modelling) ADME Tox capabilities and provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information see www.cyprotex.com.

Established in 1999, the company is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX).